Form 4: Generation Bio Merger Closes, Director Reports Holdings

Generation Bio Co. director Donald William Nicholson reports the disposition of common stock and options following the company's merger with XOMA Royalty Corporation.

Summary

• Generation Bio Co. completed its merger with XOMA Royalty Corporation's wholly-owned subsidiary, XRA 7 Corp., effective February 9, 2026.
• As a result of the merger, director Donald William Nicholson disposed of 21,357 shares of Generation Bio Co. common stock.
• Shareholders received a purchase price of $4.2913 per share in cash, plus one non-tradeable contingent value right (CVR) per share, with an estimated maximum contingent consideration of $25.01 per CVR.
• In-the-money stock options, such as 3,000 options with an exercise price of $3.874, were fully vested, cancelled, and converted into a cash payment.
• Out-of-the-money stock options, totaling 17,120 shares across various grants (e.g., 5,200 at $190, 1,500 at $265.9, 1,920 at $61.9, 2,500 at $48.3, 6,000 at $33.2), were automatically cancelled for no consideration.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as a neutral-to-slightly-positive update, confirming the expected completion of a merger that provides immediate cash and potential future value to shareholders, while also clarifying the disposition of insider holdings.

Positives

• Shareholders received an immediate cash payment of $4.2913 per share for their common stock.
• Shareholders received a non-tradeable Contingent Value Right (CVR) per share, offering potential future payments up to an estimated maximum of $25.01 per CVR.
• In-the-money stock options held by the director were converted into cash, providing value for those holdings.

Negatives

• Out-of-the-money stock options held by the director were cancelled for no consideration, resulting in a loss of potential value.
• Generation Bio Co. is now a wholly-owned subsidiary of XOMA Royalty Corporation, implying its common stock is no longer publicly traded under the GBIO ticker.

Risks

• The Contingent Value Rights (CVRs) are non-tradeable, which limits liquidity for former shareholders.
• The CVRs represent a right to receive contingent payments, meaning the actual amount received, if any, could be less than the estimated maximum of $25.01 per CVR, or even zero, depending on future events and conditions.

Future Outlook

The future value for former Generation Bio Co. shareholders is tied to the performance and conditions that trigger payments under the Contingent Value Rights agreement.

Management Comments

• The shares of common stock were exchanged for a purchase price of $4.2913 per share in cash, plus one non-tradeable contingent value right per share.
• Each in-the-money option became fully vested and was automatically cancelled and converted into the right to receive a cash amount equal to the excess of the Cash Amount over the exercise price, multiplied by the number of shares underlying the option.
• Each out-of-the-money option was automatically cancelled for no consideration.

Industry Context

StockSavvy.ai notes that the use of Contingent Value Rights (CVRs) in mergers, particularly in the biotechnology sector, is a common strategy to bridge valuation gaps between acquirer and target, allowing target shareholders to participate in the potential future success of specific assets or milestones post-acquisition. This structure can be attractive when the future value of certain pipeline assets is uncertain but potentially significant.

Comparison to Industry Standards

• The merger consideration, combining an upfront cash payment with CVRs, aligns with common practices in the biotechnology and pharmaceutical M&A landscape.
• Similar structures have been observed in acquisitions where the acquiring company seeks to mitigate risk associated with clinical development or regulatory milestones, such as the acquisition of The Medicines Company by Novartis, which included CVRs tied to inclisiran approval, or the acquisition of Alder BioPharmaceuticals by Lundbeck, which also featured CVRs.

Corporate Governance

Related Party Transactions

• The merger agreement itself constitutes a transaction between the issuer (Generation Bio Co.) and the acquiring parent company (XOMA Royalty Corporation) and its subsidiary (Merger Sub).

Stakeholder Impact

• Shareholders: Received cash and Contingent Value Rights (CVRs) for their shares.
• Option Holders: In-the-money options were cashed out, while out-of-the-money options were cancelled without consideration.
• Company: Generation Bio Co. is now a wholly-owned subsidiary of XOMA Royalty Corporation, changing its operational and reporting structure.

Next Steps

• Potential future contingent payments to CVR holders based on the terms and conditions of the contingent value rights agreement.

Key Dates

Keywords

Generation Bio Co., GBIO, XOMA Royalty Corporation, Merger, Acquisition, Tender Offer, Form 4, Insider Transaction, Stock Options, Contingent Value Right, CVR, Corporate Action